Microrna-486-5P Regulates Human Pulmonary Artery Smooth Muscle Cell Migration via Endothelin-1.
Ting-An YenHsin-Chung HuangEn-Ting WuHeng-Wen ChouHung-Chieh ChouChien-Yi ChenShu-Chien HuangYih Sharng ChenFrank-Leigh LuMei-Hwan WuPo-Nien TsaoChing-Chia WangPublished in: International journal of molecular sciences (2022)
Pulmonary arterial hypertension (PAH) is a fatal or life-threatening disorder characterized by elevated pulmonary arterial pressure and pulmonary vascular resistance. Abnormal vascular remodeling, including the proliferation and phenotypic modulation of pulmonary artery smooth muscle cells (PASMCs), represents the most critical pathological change during PAH development. Previous studies showed that miR-486 could reduce apoptosis in different cells; however, the role of miR-486 in PAH development or HPASMC proliferation and migration remains unclear. After 6 h of hypoxia treatment, miR-486-5p was significantly upregulated in HPASMCs. We found that miR-486-5p could upregulate the expression and secretion of ET-1. Furthermore, transfection with a miR-486-5p mimic could induce HPASMC proliferation and migration. We also found that miRNA-486-5p could downregulate the expression of SMAD2 and the phosphorylation of SMAD3. According to previous studies, the loss of SMAD3 may play an important role in miRNA-486-5p-induced HPASMC proliferation. Although the role of miRNA-486-5p in PAH in in vivo models still requires further investigation and confirmation, our findings show the potential roles and effects of miR-486-5p during PAH development.
Keyphrases
- pulmonary artery
- pulmonary arterial hypertension
- pulmonary hypertension
- coronary artery
- smooth muscle
- polycyclic aromatic hydrocarbons
- long non coding rna
- cell migration
- poor prognosis
- epithelial mesenchymal transition
- cell proliferation
- cell cycle arrest
- transforming growth factor
- endothelial cells
- signaling pathway
- induced apoptosis
- oxidative stress
- endoplasmic reticulum stress
- cell death
- high glucose
- drug induced
- risk assessment
- induced pluripotent stem cells